These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 8695352

  • 21. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA.
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [Abstract] [Full Text] [Related]

  • 22. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    Mellish KJ, Barnard CF, Kelland LR, Harrap KR.
    Int J Cancer; 1994 Oct 01; 59(1):65-70. PubMed ID: 7927906
    [Abstract] [Full Text] [Related]

  • 23. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR.
    Cancer Res; 1992 Nov 15; 52(22):6188-93. PubMed ID: 1423261
    [Abstract] [Full Text] [Related]

  • 24. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR.
    Cancer Chemother Pharmacol; 1994 Nov 15; 35(2):137-43. PubMed ID: 7987990
    [Abstract] [Full Text] [Related]

  • 25. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
    O'Neill CF, Ormerod MG, Robertson D, Titley JC, Cumber-Walsweer Y, Kelland LR.
    Br J Cancer; 1996 Oct 15; 74(7):1037-45. PubMed ID: 8855971
    [Abstract] [Full Text] [Related]

  • 26. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
    Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR.
    Br J Cancer; 1998 Oct 15; 77(3):366-73. PubMed ID: 9472630
    [Abstract] [Full Text] [Related]

  • 27. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 15; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 28. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
    Reardon JT, Vaisman A, Chaney SG, Sancar A.
    Cancer Res; 1999 Aug 15; 59(16):3968-71. PubMed ID: 10463593
    [Abstract] [Full Text] [Related]

  • 29. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG.
    Cancer Res; 1992 Dec 15; 52(24):6885-9. PubMed ID: 1458477
    [Abstract] [Full Text] [Related]

  • 30. The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.
    Ormerod MG, Orr RM, O'Neill CF, Chwalinski T, Titley JC, Kelland LR, Harrap KR.
    Br J Cancer; 1996 Dec 15; 74(12):1935-43. PubMed ID: 8980393
    [Abstract] [Full Text] [Related]

  • 31. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.
    Amorino GP, Freeman ML, Carbone DP, Lebwohl DE, Choy H.
    Int J Radiat Oncol Biol Phys; 1999 May 01; 44(2):399-405. PubMed ID: 10760436
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB.
    Cancer Chemother Pharmacol; 2007 Feb 01; 59(3):301-12. PubMed ID: 16770583
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH.
    Clin Cancer Res; 1999 Mar 01; 5(3):655-63. PubMed ID: 10100719
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.